Aurinia Pharmaceuticals Inc (AUPH)
8.84
+0.07
(+0.80%)
USD |
NASDAQ |
Nov 22, 13:30
Aurinia Pharmaceuticals Net Income (Quarterly): 14.35M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 14.35M |
| June 30, 2024 | 0.722M |
| March 31, 2024 | -10.75M |
| December 31, 2023 | -26.88M |
| September 30, 2023 | -13.45M |
| June 30, 2023 | -11.49M |
| March 31, 2023 | -26.21M |
| December 31, 2022 | -26.05M |
| September 30, 2022 | -8.989M |
| June 30, 2022 | -35.52M |
| March 31, 2022 | -37.63M |
| December 31, 2021 | -33.32M |
| September 30, 2021 | -50.26M |
| June 30, 2021 | -47.01M |
| March 31, 2021 | -50.38M |
| December 31, 2020 | -8.074M |
| September 30, 2020 | -42.13M |
| June 30, 2020 | -26.54M |
| March 31, 2020 | -25.93M |
| December 31, 2019 | -41.02M |
| September 30, 2019 | -19.04M |
| June 30, 2019 | -15.90M |
| March 31, 2019 | -12.43M |
| December 31, 2018 | -3.552M |
| September 30, 2018 | -18.34M |
| Date | Value |
|---|---|
| June 30, 2018 | -15.71M |
| March 31, 2018 | -15.48M |
| December 31, 2017 | -3.332M |
| September 30, 2017 | -13.12M |
| June 30, 2017 | -2.399M |
| March 31, 2017 | -51.94M |
| December 31, 2016 | -8.333M |
| September 30, 2016 | -7.419M |
| June 30, 2016 | -3.276M |
| March 31, 2016 | -4.267M |
| December 31, 2015 | -4.063M |
| September 30, 2015 | -5.21M |
| June 30, 2015 | -0.733M |
| March 31, 2015 | -8.601M |
| December 31, 2014 | -8.105M |
| September 30, 2014 | 4.438M |
| June 30, 2014 | -11.03M |
| March 31, 2014 | -4.775M |
| December 31, 2013 | -1.698M |
| September 30, 2013 | 0.792M |
| June 30, 2013 | -0.97M |
| March 31, 2013 | -0.786M |
| December 31, 2012 | -5.166M |
| September 30, 2012 | -1.729M |
| June 30, 2012 | -2.304M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-50.38M
Minimum
Mar 2021
14.35M
Maximum
Sep 2024
-25.33M
Average
-26.38M
Median
Net Income (Quarterly) Benchmarks
| Edesa Biotech Inc | -1.668M |
| Lexaria Bioscience Corp | -1.782M |
| Xenon Pharmaceuticals Inc | -62.79M |
| ESSA Pharma Inc | -7.234M |
| ImmunoPrecise Antibodies Ltd | -2.920M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 67.77M |
| Total Expenses (Quarterly) | 56.02M |
| EPS Diluted (Quarterly) | 0.10 |
| Enterprise Value | 906.94M |
| Gross Profit Margin (Quarterly) | 91.10% |
| Profit Margin (Quarterly) | 21.17% |
| Earnings Yield | -1.58% |
| Normalized Earnings Yield | -1.103 |